Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies
Author:
Publisher
Elsevier BV
Reference185 articles.
1. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study;Abramson;Lancet Lond. Engl.,2020
2. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells;Alcantara;Leukemia,2018
3. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions;Antar;Leukemia,2020
4. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors;Bae;Leukemia,2018
5. Phase 1 trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma;Baumeister;Cancer Immunol. Res.,2019
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advancement in “Off-the-Shelf” CAR T-Cell Therapy for Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28
2. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy;Molecular Cancer;2024-08-26
3. Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination;Cancer Letters;2024-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3